# MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine

> **NCT05197751** · PHASE1 · UNKNOWN · sponsor: **Vac4All** · enrollment: 42 (estimated)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **BIOLOGICAL:** MSP3-CRM-Vac4All/ Alhydrogel®

## Key facts

- **NCT ID:** NCT05197751
- **Lead sponsor:** Vac4All
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-08-03
- **Final completion:** 2023-05-09
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05197751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05197751, "MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05197751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*